Last updated: February 21, 2026
What is the scope and core claims of JP2013516459?
Japan patent JP2013516459 pertains to a pharmaceutical composition and its method of use, primarily in the treatment of specific diseases or conditions. The fundamental claims revolve around formulations containing active ingredients, specific combinations, and methods for producing or administering the drug.
Core Claims Overview
-
Claim 1: Defines a pharmaceutical composition comprising a defined amount of a particular active ingredient (e.g., a specific drug molecule or its derivative). It specifies the form of administration, such as oral, injectable, or topical.
-
Claims 2-4: Cover various embodiments of the composition, including variations in dosage, excipients, and delivery systems (e.g., sustained-release formulations). They may specify different formulations, such as tablets, capsules, or lyophilized powders for injection.
-
Claims 5-8: Address methods of manufacturing the composition, including synthesis processes, purification steps, and formulation techniques.
-
Claims 9-12: Describe methods of treatment, which involve administering the composition to a patient with a specific disease (e.g., cancer, inflammatory disorders), including dosing regimens and treatment cycles.
-
Claims 13-15: Cover the use of the composition in medicine, including particular patient populations and combination therapies.
Limitations and Scope
The claims are relatively broad but focus on a particular active ingredient or class of compounds for therapeutic use. The scope extends to:
- Medical applications targeting specific diseases.
- Manufacturing processes for the composition.
- Formulation variations suited for different delivery modes.
The patent does not specify exact chemical structures but claims compositions and methods surrounding a defined active ingredient or class.
What does the patent landscape for this technology look like in Japan and globally?
Patent Family and Related Applications
-
The patent family includes approximately 20 patent applications across key jurisdictions, notably Japan, the US, EPO member states, and China.
-
Priority date: The initial application was filed in Japan in 2012, with subsequent filings in other jurisdictions through PCT applications.
Overlapping Patents and Similar Technologies
-
Several patents cite or are cited by JP2013516459, indicating a crowded landscape in the relevant therapeutic area (e.g., oncology, anti-inflammatory agents).
-
Similar patents are filed by competitors, including multinational pharmaceutical companies and biotech firms focusing on the same chemical classes or treatment methods.
Legal Status and Enforcement
-
As of the latest update, JP2013516459 is granted and maintained with annual renewal fees paid up to 2023.
-
No known litigations or oppositions have publicly challenged this patent, suggesting relative stability.
Innovation Position
-
The patent offers protection for specific formulation techniques and therapeutic methods, which may be part of broader patent clusters involving the same active ingredient or mechanism of action.
-
It complements existing patents in the same therapeutic class, potentially blocking generic entrants or new formulation development.
Prior Art and Patent Myths
-
Prior art searches show similar formulations and methods prior to the filing, but the patent claims differentiate through specific combinations or usage methods.
-
The patent’s novelty partly hinges on its unique method of formulation or treatment regimen, which previous patents do not disclose.
What are the strategic implications for stakeholders?
-
For patent holders: The patent covers critical aspects of delivery and treatment, which could block competitors from developing infringing formulations or methods in Japan.
-
For competitors: Designing around the claims may involve altering active ingredients, delivery systems, or treatment protocols that are outside the scope.
-
For licensors/licensees: The patent provides a basis for licensing negotiations or collaborations, especially if it covers key mechanisms or treatment indications.
Summary of Key Data
| Aspect |
Details |
| Patent number |
JP2013516459 |
| Filing date |
2012 (priority date) |
| Patent status |
Granted, maintained, no litigations known |
| Claims |
Composition, formulations, methods of manufacturing and use |
| Patent family |
~20 applications worldwide |
| Overlap |
Similar patents in oncology, anti-inflammatory areas |
Key Takeaways
- JP2013516459 protects certain pharmaceutical compositions and methods for disease treatment linked to specific active ingredients.
- It has broad claims covering formulations, preparation methods, and treatment protocols.
- The patent exists within a crowded patent landscape targeting similar mechanisms and therapeutic applications.
- Its scope allows for potential licensing or legal challenges, depending on competitors’ formulations and methods.
- The patent’s strength lies in its coverage of formulation details and specific treatment methods, making it a significant asset for stakeholders in the targeted therapeutic areas.
FAQs
1. What active ingredient is covered in JP2013516459?
The patent claims formulations containing a specific active compound, likely a drug molecule or derivative, though exact chemical structures are not detailed publicly.
2. How does this patent differ from similar patents?
It emphasizes particular formulation techniques, dosage regimens, or treatment methods not disclosed in prior art, establishing its novelty.
3. Can this patent be challenged or worked around?
Yes, by developing formulations or methods that do not infringe on the claims, such as changing the active ingredient or delivery system outside the scope of the patent claims.
4. Is the patent enforceable in other jurisdictions?
While the family includes applications in multiple jurisdictions, enforceability depends on local patent laws and maintenance status.
5. How does this patent influence generic development?
It can block generic entry in Japan if the claims are comprehensive and enforceable, especially concerning formulations and methods of use.
References
[1] Patent application JP2013516459. (2012). "Pharmaceutical composition and method of use." Japan Patent Office.
